Cognitive function in postmenopausal women receiving letrozole or tamoxifen as adjuvant endocrine treatment was compared during the fifth year of treatment in a substudy of the BIG 1-98 trial. In BIG 1-98 patients were randomized to receive adjuvant (A) 5-years tamoxifen, (B) 5-years letrozole, (C) 2-years tamoxifen followed by 3-years letrozole, or (D) 2-years letrozole followed by 3-years tam...

OBJECTIVE To compare the pregnancy rates with two different methods of priming for in vitro maturation cycles (IVM). Cycles using letrozole together with hCG were compared to cycles using FSH together with hCG in 75 cycles in patients being treated for infertility by IVM. STUDY DESIGN Retrospective cohort non-inferiority trial Results: Using letrozole for priming was found to not be inferior ...

Relapse after completing adjuvant tamoxifen therapy is a persistent threat for women with hormoneresponsive breast cancer. Third-generation aromatase inhibitors, such as letrozole, provide a new option for extended adjuvant hormonal therapy after 5 years of tamoxifen. MA.17 was conducted to determine whether letrozole improves outcome after discontinuation of tamoxifen. Postmenopausal women wit...

BACKGROUND Letrozole is the third-generation aromatase inhibitor (AI) most widely used in assisted reproduction. AIs induce ovulation by inhibiting estrogen production; the consequent hypoestrogenic state increases GnRH release and pituitary follicle-stimulating hormone (FSH) synthesis. METHODS A systematic search of the literature was performed for both prospective and retrospective studies....

Background: Clomiphen citrate (CC) is the first line therapy for women with infertility and poly cystic ovary syndrome( PCOS).However, 20-25% of women are resistant to CC and do not ovulate. The Background of this study is to evaluate the efficacy of sequential treatment of metformin and incremental doses of letrozole in induction of ovulation in cases of clomiphen citrateresistant (CC- R) PCOS...

OBJECTIVETo determine the pregnaflcy outcome with letrozole as an ovulation inducing agent in infertile pa tients. METHOD A Randomized clinical trial was conducted on 250infertile patients attending the outpatient department. Letrozole wa s administered as 5 mg tablets from day 3 to 7 of menstruation after a preliminary day 2 LH level and baseline ultrasound. RESULTS Letrozole given alone had a...

Blocking estrogen receptors with antiestrogens and blocking estrogen synthesis with aromatase inhibitors are two strategies currently being used for reducing the effect of estrogen in postmenopausal estrogen receptor-positive breast cancer patients. To optimize these treatment strategies, we have investigated whether tumor progression can be delayed by combining the pure antiestrogen fulvestran...

BACKGROUND Medication policy development in Thailand is continually promoting rational drug use. Letrozole, an endocrine therapy drug, is usually prescribed for post-menopausal status early and advanced stage breast cancer. After Ministry of Public Health announced Letrozole as compulsory licensed drug in 2009, more breast cancer patients can access to this drug at low cost especially those wit...

INTRODUCTION Letrozole is being used as an alternative to clomiphene citrate in women with polycystic ovary syndrome (PCOS) requiring ovulation induction. Berberine, a major active component of Chinese herbal medicine rhizoma coptidis, has been used to improve insulin resistance to facilitate ovulation induction in women with PCOS but there is no study reporting the live birth or its potential ...